<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2021.101001</article-id><article-id pub-id-type="publisher-id">TCM-39654</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20210100000_30750618.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  探析越鞠丸和柴胡疏肝散“同病异治”抑郁症的作用机制
  Analysis of Antidepressant Mechanism of Yueju Pill and Chaihu Shugan Powder in Treating Depression with “the Same Disease with Different Treatments”
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黄</surname><given-names>志航</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>文雯</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>钟</surname><given-names>馨</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>木</surname><given-names>本荣</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>冬梅</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>国</surname><given-names>锦琳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>成都中医药大学，四川 成都</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>01</month><year>2021</year></pub-date><volume>10</volume><issue>01</issue><fpage>1</fpage><lpage>13</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：基于网络药理学和生物信息学方法探讨越鞠丸和柴胡疏肝散“同病异治”抑郁症的作用机制。方法：利用TCMID、Batman-TCM获取越鞠丸与柴胡疏肝散各自的有效活性成分和作用靶点；通过基因表达集(GEO)芯片数据库筛选抑郁症差异基因，DrugBank、GeneCards、OMIM、TTD筛选抑郁症相关靶点基因；运用Cytoscape和String构建靶点相互作用网络PPI，并通过Cytoscape的Network Analyzer工具对靶点进行拓扑分析，插件ClusterViz的MCODE算法进行模块分析；利用DAVID对靶点进行GO和KEGG分析。结果：两个方剂中有310个共同靶点与抑郁症有关，越鞠丸特有抗抑靶点有20个，柴胡疏肝散特有抗抑靶点有52个。这两种药物可能通过INS、ALB、BDNF、IL6、FOS等关键蛋白所在的神经活性配体–受体相互作用、Calcium信号通路和细胞缝隙连接等发挥抗抑郁的作用。越鞠丸的特有靶点SCNN1G、SCNN1B、SCNN1A所在的醛固酮调节的钠重吸收、味觉转导信号通路揭示了抗抑郁机制；柴胡疏肝散的特有靶点AKT1、HRAS、MAPK1蛋白所在的癌症通路、ErbB信号通路等揭示了不同的抗抑郁机制。结论：越鞠丸和柴胡疏肝散由于组分差异，既可以通过相同靶点抗抑郁，也可以通过特有靶点抗抑郁。本研究对两种方剂中药物靶点和通路进行可视化网络分析，进而初步阐明“同病异治”抑郁症的科学内涵。 Objective: Based on network pharmacology and bioinformatics methods, to explore the mechan-ism of Yueju Pill and Chaihu Shugan Powder in treating depression in “the same disease with dif-ferent treatments”. Methods: TCMID and Batman-TCM were used to obtain the active components and targets of Yueju Pill and Chaihu Shugan Powder respectively; use Gene Expression Omnibus (GEO) and genetic disease databases to screen the differences of genes in depression; use DrugBank, Gene Cards, OMIM, TDD to screen related proteins to depression; use Cytoscape and String to construct the protein interaction network (PPI). Through the Network Analyzer tool of Cytoscape, the topology of the target was analyzed, and ClusterViz’s MCODE algorithm was used for module analysis; use DAVID for GO and KEGG analysis of targets. Results: Among the two formulations, 310 common targets were related to depression, among which 20 were specific anti-depressants of Yueju Pill and 52 were specific anti-depressants of Chaihu Shugan Powder. These two drugs may play an antidepressant role in the neural-active ligand-receptor interactions and Calcium signaling pathways of key proteins such as INS, ALB, BDNF, IL6, FOS and so on. The aldosterone regulating sodium reabsorption and taste transduction pathways of the specific targets SCNN1G, SCNN1B and SCNN1A of Yueju Pill revealed the antidepressant mechanism; AKT1, HRAS, MAPK1 in the cancer pathways and ErbB signaling pathways, which are specific targets of Chaihu Shugan Powder, reveal different antidepressant mechanisms. Conclusion: Due to the difference in components, Yueju Pill and Chaihu Shugan Powder can be used as anti-depressants at the same or specific targets. In this study, the visual network analysis of drug targets and pathways in the two formulations was carried out to preliminarily clarify the scientific connotation of “treating depression in the same disease with different treatments”. 
  
 
</p></abstract><kwd-group><kwd>越鞠丸，柴胡疏肝散，抑郁症，同病异治，网络药理学，生物信息学, Yueju Pill</kwd><kwd> Chaihu Shugan Powder</kwd><kwd> Depression</kwd><kwd> The Same Disease with Different Treatments</kwd><kwd> Network Pharmacology</kwd><kwd> Bioinformatics</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：基于网络药理学和生物信息学方法探讨越鞠丸和柴胡疏肝散“同病异治”抑郁症的作用机制。方法：利用TCMID、Batman-TCM获取越鞠丸与柴胡疏肝散各自的有效活性成分和作用靶点；通过基因表达集(GEO)芯片数据库筛选抑郁症差异基因，DrugBank、GeneCards、OMIM、TTD筛选抑郁症相关靶点基因；运用Cytoscape和String构建靶点相互作用网络PPI，并通过Cytoscape的Network Analyzer工具对靶点进行拓扑分析，插件ClusterViz的MCODE算法进行模块分析；利用DAVID对靶点进行GO和KEGG分析。结果：两个方剂中有310个共同靶点与抑郁症有关，越鞠丸特有抗抑靶点有20个，柴胡疏肝散特有抗抑靶点有52个。这两种药物可能通过INS、ALB、BDNF、IL6、FOS等关键蛋白所在的神经活性配体–受体相互作用、Calcium信号通路和细胞缝隙连接等发挥抗抑郁的作用。越鞠丸的特有靶点SCNN1G、SCNN1B、SCNN1A所在的醛固酮调节的钠重吸收、味觉转导信号通路揭示了抗抑郁机制；柴胡疏肝散的特有靶点AKT1、HRAS、MAPK1蛋白所在的癌症通路、ErbB信号通路等揭示了不同的抗抑郁机制。结论：越鞠丸和柴胡疏肝散由于组分差异，既可以通过相同靶点抗抑郁，也可以通过特有靶点抗抑郁。本研究对两种方剂中药物靶点和通路进行可视化网络分析，进而初步阐明“同病异治”抑郁症的科学内涵。</p></sec><sec id="s2"><title>关键词</title><p>越鞠丸，柴胡疏肝散，抑郁症，同病异治，网络药理学，生物信息学</p></sec><sec id="s3"><title>Analysis of Antidepressant Mechanism of Yueju Pill and Chaihu Shugan Powder in Treating Depression with “the Same Disease with Different Treatments”<sup> </sup></title><p>Zhihang Huang<sup>*</sup>, Wenwen Liu<sup>*</sup>, Xin Zhong, Benrong Mu, Dongmei Wang<sup>#</sup>, Jinlin Guo<sup>#</sup></p><p>Chengdu University of Traditional Chinese Medicine, Chengdu Sichuan</p><p><img src="//html.hanspub.org/file/1-2270612x5_hanspub.png" /></p><p>Received: Nov. 17<sup>th</sup>, 2020; accepted: Dec. 25<sup>th</sup>, 2020; published: Jan. 5<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/1-2270612x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: Based on network pharmacology and bioinformatics methods, to explore the mechanism of Yueju Pill and Chaihu Shugan Powder in treating depression in “the same disease with different treatments”. Methods: TCMID and Batman-TCM were used to obtain the active components and targets of Yueju Pill and Chaihu Shugan Powder respectively; use Gene Expression Omnibus (GEO) and genetic disease databases to screen the differences of genes in depression; use DrugBank, Gene Cards, OMIM, TDD to screen related proteins to depression; use Cytoscape and String to construct the protein interaction network (PPI). Through the Network Analyzer tool of Cytoscape, the topology of the target was analyzed, and ClusterViz’s MCODE algorithm was used for module analysis; use DAVID for GO and KEGG analysis of targets. Results: Among the two formulations, 310 common targets were related to depression, among which 20 were specific anti-depressants of Yueju Pill and 52 were specific anti-depressants of Chaihu Shugan Powder. These two drugs may play an antidepressant role in the neural-active ligand-receptor interactions and Calcium signaling pathways of key proteins such as INS, ALB, BDNF, IL6, FOS and so on. The aldosterone regulating sodium reabsorption and taste transduction pathways of the specific targets SCNN1G, SCNN1B and SCNN1A of Yueju Pill revealed the antidepressant mechanism; AKT1, HRAS, MAPK1 in the cancer pathways and ErbB signaling pathways, which are specific targets of Chaihu Shugan Powder, reveal different antidepressant mechanisms. Conclusion: Due to the difference in components, Yueju Pill and Chaihu Shugan Powder can be used as anti-depressants at the same or specific targets. In this study, the visual network analysis of drug targets and pathways in the two formulations was carried out to preliminarily clarify the scientific connotation of “treating depression in the same disease with different treatments”.</p><p>Keywords:Yueju Pill, Chaihu Shugan Powder, Depression, The Same Disease with Different Treatments, Network Pharmacology, Bioinformatics</p><disp-formula id="hanspub.39654-formula4"><graphic xlink:href="//html.hanspub.org/file/1-2270612x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-2270612x8_hanspub.png" /> <img src="//html.hanspub.org/file/1-2270612x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>抑郁症(depressive disorder)又称为抑郁障碍，它是由于多种复杂原因所造成的一种心理疾病，主要以心境低落、活动衰退、思维迟钝为主要的发病症状。2008年世界卫生组织将重度抑郁列为全球第三大疾病。由于信息化时代发展，社会舆论暴力加剧，抑郁症已经成为了全球关注并重视的疾病，及时发现并治疗，有助于改善和提高抑郁症的疗效。</p><p>临床上西医治疗抑郁症用药包括丙米嗪、阿米替林、多塞平等，但连续服用西药起效时间长，停药后也易反复，可能还会出现无力、头晕、反射亢进、共济失调、肌肉震颤等不良反应，大剂量使用时甚至可能刺激中枢系统出现精神亢奋。而中医结合活血、清热、祛湿、消食和祛痰等法治疗 [<xref ref-type="bibr" rid="hanspub.39654-ref1">1</xref>]。目前国内大多数学者认为，抑郁症的病因在于肝脏，所以可以通过服用透邪解郁的四逆散 [<xref ref-type="bibr" rid="hanspub.39654-ref2">2</xref>]、调气疏肝解郁散结的柴胡疏肝散 [<xref ref-type="bibr" rid="hanspub.39654-ref3">3</xref>]，理气解郁的越鞠丸 [<xref ref-type="bibr" rid="hanspub.39654-ref4">4</xref>] 等方剂，起到疏肝解郁、宽胸理气的作用。相较于西医，中医治疗疾病的优势就在于注重未病先防 [<xref ref-type="bibr" rid="hanspub.39654-ref5">5</xref>]，整体调理，各种药材活性成分相辅相成又互相制约，养护自身抵御外邪的正气，提高自身的抵抗力，防止人体功能紊乱，有效维护身体健康。中医药治疗疾病因其具有“多成分–多靶点–多途径调节”和善于采用整体与辩证观相结合的方法来治疗疾病的特点，在治疗成因不明确的复杂疾病方面具有独特优势。目前，中药方剂治疗抑郁症已有相关研究得到证实，但对于中药方剂“同病异治”抑郁症的科学内涵还尚未明确。</p><p>“同病异治”概念早在《素问&#183;病能论》 [<xref ref-type="bibr" rid="hanspub.39654-ref6">6</xref>] 中有云：“有病颈痈者，或石治之，或针灸治之，而皆已，其真安在？岐伯曰：此同名异等者也。夫痈气之息者，宜以针开除去之；夫气盛血聚者，宜石而写之。此所谓同病异治也。”同病异治，即同一种疾病因为个体差异或是病情变化而采取不一样的治疗方法，不同的治疗方法却有一样的缓解或治愈疗效，这是中医治疗的一大特色，也是一大成功治疗疾病的方法实操。但是通过单一的方法不能有效解释“同病异治”疾病的作用机制，所以需要一种能够将多种药物成分和靶点与疾病联系起来的研究方法。</p><p>网络药理学是一种新兴的以整体性、系统性为特点的网络分析研究方法。它可以通过搜索整合药物信息，从而揭示中药对机体调控机制 [<xref ref-type="bibr" rid="hanspub.39654-ref7">7</xref>]。生物信息学同样作为新兴学科，运用计算机信息技术开发新的算法和统计方法以及数据库对生物学信息和数据进行整合分析 [<xref ref-type="bibr" rid="hanspub.39654-ref8">8</xref>]，利用数据处理方法挖掘更多隐含的生物学意义。针对方剂“多成分–多靶点–多途径调节”的特点，筛选药物多成分和疾病靶点，对信号通路的多途径调节进行分析，进而探究中药与疾病的作用机制。目前，国内已有部分学者采用网络药理学和生物信息学对中药方剂治疗疾病作用机制进行探究，证实了方法的可行性，为探究越鞠丸和柴胡疏肝散“同病异治”抑郁症的真正科学内涵奠定了坚实的基础。</p><p>本研究采用网络药理学和生物信息学数据挖掘方法，通过筛选整合药物有效活性成分靶点和疾病靶点，对活性成分共有和特有的抗抑郁靶点及通路进行分析，从而阐释越鞠丸和柴胡疏肝散对抑郁症“同病异治”的作用机制和科学内涵。</p></sec><sec id="s6"><title>2. 研究对象和方法</title><sec id="s6_1"><title>2.1. 越鞠丸和柴胡疏肝散化学成分的收集</title><p>越鞠丸由香附、苍术、川芎、栀子、六神曲5味中药组成，柴胡疏肝散由陈皮、柴胡、白芍、香附、枳壳、川芎、甘草7味中药组成。在中药化学数据库Batman-TCM (http://bionet.ncpsb.org/batman-tcm/) [<xref ref-type="bibr" rid="hanspub.39654-ref9">9</xref>]、TCMID (http://www.megabionet.org/tcmid/) [<xref ref-type="bibr" rid="hanspub.39654-ref10">10</xref>] 中通过运用网络药理学和生物信息学数据挖掘方法搜索整合收集越鞠丸和柴胡疏肝散各个组分的有效化学成分。同时应用Batman-TCM在线分析平台，搜索越鞠丸和柴胡疏肝散的单味药组分中对应的靶点，对于每一个组分的化学成分，只考虑评分不小于20分的预测靶点，同时删除无有效靶点的成分。此外，由于越鞠丸中六神曲成分是多种药材按比例混合再发酵制成的曲剂，存在许多真菌和细菌，因此其药效并非基于“成分–靶点”的原则来发挥，而可能通过调节肠道菌群来发挥作用，故暂时无法基于平台进行分析 [<xref ref-type="bibr" rid="hanspub.39654-ref11">11</xref>]。所以，本研究只分析越鞠丸的4种成分，不包括六神曲。</p></sec><sec id="s6_2"><title>2.2. 抑郁症差异基因的筛选</title><p>在美国国立生物中心(National Center for Biotechnology Information, NCBI)中的GEO (Gene Expression Ominibus)数据库(www.ncbi.nlm.nih.gov/geo)检索抑郁症相关芯片，找到编码为GSE44593 (Organisms: Homo sapiens)的基因芯片数据，该芯片数据包括疾病组14例抑郁症患者、对照组14例正常对照者的基因，共28个样本。本研究采用R语言编limma软件包对该基因芯片数据进行分析，默认参数设置P value &lt; 0.05，筛选出抑郁症差异表达基因。</p></sec><sec id="s6_3"><title>2.3. 抑郁症靶点的筛选</title><p>利用DrugBank (https://www.drugbank.ca/) [<xref ref-type="bibr" rid="hanspub.39654-ref12">12</xref>]、GeneCards (http://www.genecards.org/) [<xref ref-type="bibr" rid="hanspub.39654-ref13">13</xref>]、OMIM (http://omim.org/) [<xref ref-type="bibr" rid="hanspub.39654-ref14">14</xref>]、TTD (http://bidd.nus.edu.sg/group/cjttd/) [<xref ref-type="bibr" rid="hanspub.39654-ref15">15</xref>] 4个数据库，结合上述差异表达基因，归纳整合筛选抗抑靶点。</p></sec><sec id="s6_4"><title>2.4. 成分–靶点网络的构建</title><p>整理上述筛选结果，删除重复的靶点。采用Cytoscape3.7.2 (http://www.cytoscape.org/)构建越鞠丸–柴胡疏肝散成分–靶点网络，得到越鞠丸和柴胡疏肝散成分与靶点之间相关性的可视化关系图。</p></sec><sec id="s6_5"><title>2.5. 共有靶点和特有靶点网络的构建</title><p>使用String 11.0 (http://string-db.org/)在线工具获取共有靶点之间的相互作用关系、特有靶点之间的相互作用关系，再导入Cytoscape 3.7.2软件构建共有抗抑靶点蛋白质与蛋白质相互作用网络(Protein-Protein Interaction, PPI)、两种中药方剂特有抗抑靶点PPI，其中用“节点”来表示作用靶点，“边”来表示靶点与靶点之间的关系。节点对应的边越多，表示该节点在整个网络中可能具有重要的作用。通过对共有靶点和特有靶点的网络构建分析，能够更好的阐释“同病异治”的作用机制和科学内涵。</p></sec><sec id="s6_6"><title>2.6. 网络的分析</title><p>运用Cytoscape3.7.2软件中的工具Network Analyzer来进行拓扑分析，以评价越鞠丸和柴胡疏肝散的共同抗抑靶点。其中有两个重要参数包括节点中心度和点的连接度。节点中心度用以衡量节点在网络中的中心程度，点的连接度是指该网络中与该点相连接的边的数量。运用Cytoscape中的ClusterViz进行模块分析，选择MCODE算法进行聚类分析 [<xref ref-type="bibr" rid="hanspub.39654-ref16">16</xref>]。K-Core是决定识别模块大小的参数，将参数K-Core设置为4，即获得的模块所对应的边应大于4，从而寻找靶点与靶点之间的相互联系。</p></sec><sec id="s6_7"><title>2.7. 预测靶点的GO和KEGG通路分析</title><p>利用DAVID 6.7 (https://david.ncifcrf.gov/) [<xref ref-type="bibr" rid="hanspub.39654-ref17">17</xref>] 对筛选到的共有抗抑靶点和特有抗抑靶点进行GO和KEGG分析，得到靶点富集结果和所在信号通路，并用GraphPad Prism 8绘图。</p></sec></sec><sec id="s7"><title>3. 结果与分析</title><sec id="s7_1"><title>3.1. 越鞠丸和柴胡疏肝散成分筛选的靶点</title><p>利用Batman-TCM和TCMID两个数据库筛选靶点，去除没有对应靶点的成分。越鞠丸和柴胡疏肝散中成分和靶点统计见表1。结果显示越鞠丸的化学成分和靶点分别为132个、1247个，柴胡疏肝散的化学成分和靶点分别为305个、1413个。越鞠丸和柴胡疏肝散共有的化学成分和靶点是104个、1140个。其中，香附和川芎为两药共有的两种组分，对应的化学成分和靶点分别为 12个、91个和449个、958个。越鞠丸特有的化学成分和靶点分别是27个、107个；柴胡疏肝散特有的化学成分和靶点分别是175个、273个。越鞠丸–柴胡疏肝散成分–靶点网络(图1)其中有299个有效成分节点，1473个靶点节点和6691条边线。有效成分与靶点之间相互联系，且多个靶点对应多个成分，体现了中药方剂以“多成分–多靶点–多途径调节”的特点。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Statistics of components and targets of Yueju Pill and Chaihu Shugan Powde</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >复方</th><th align="center" valign="middle" >单味药</th><th align="center" valign="middle" >成分数目</th><th align="center" valign="middle" >靶点数目</th></tr></thead><tr><td align="center" valign="middle"  rowspan="5"  >越鞠丸</td><td align="center" valign="middle" >香附</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >449</td></tr><tr><td align="center" valign="middle" >苍术</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >315</td></tr><tr><td align="center" valign="middle" >川芎</td><td align="center" valign="middle" >91</td><td align="center" valign="middle" >958</td></tr><tr><td align="center" valign="middle" >栀子</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >664</td></tr><tr><td align="center" valign="middle" >合计</td><td align="center" valign="middle" >132</td><td align="center" valign="middle" >1247</td></tr><tr><td align="center" valign="middle"  rowspan="8"  >柴胡疏肝散</td><td align="center" valign="middle" >陈皮</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >603</td></tr><tr><td align="center" valign="middle" >柴胡</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" >1097</td></tr><tr><td align="center" valign="middle" >白芍</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >123</td></tr><tr><td align="center" valign="middle" >香附</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >449</td></tr><tr><td align="center" valign="middle" >枳壳</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >342</td></tr><tr><td align="center" valign="middle" >川芎</td><td align="center" valign="middle" >91</td><td align="center" valign="middle" >958</td></tr><tr><td align="center" valign="middle" >甘草</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >690</td></tr><tr><td align="center" valign="middle" >合计</td><td align="center" valign="middle" >305</td><td align="center" valign="middle" >1413</td></tr></tbody></table></table-wrap><p>表1. 越鞠丸和柴胡疏肝散成分和靶点统计</p><p>图1. 成分–靶点网络。A1——越鞠丸特有成分；A2——柴胡疏肝散特有成分；A3——香附、川芎成分；A4——非香附、川芎共有成分；B1——鞠丸特有靶点；B2——香附、川芎靶点；B3——非香附、川芎共有靶点；B4——柴胡疏肝散特有靶点</p></sec><sec id="s7_2"><title>3.2. 抑郁症相关基因分析与抑郁症靶点的分析</title><p>进入GEO数据库，下载GSE44593基因芯片数据，用R语言对其进行数据分析，筛选前50个差异基因，并绘制前50个差异基因热图(图2)。通过对疾病数据库的检索，筛选出抑郁症靶点有1630个。其中有310个共同靶点与抑郁症有关，20个越鞠丸特有靶点和52个柴胡疏肝散特有靶点与抑郁症有关。再运用String工具绘制共有抗抑靶点网络作用图(图3)，有309个节点和5293条边。越鞠丸特有抗抑靶点作用图有10个节点和11条边(图4)。柴胡疏肝散特有抗抑靶点作用网络(图5)有47个节点和160条边。</p><p>图2. 前50个差异表达基因热图</p><p>图3. 共有靶点作用网络图</p><p>图4. 越鞠丸特有抗抑靶点作用网络图</p><p>图5. 柴胡疏肝散特有抗抑靶点作用网络图</p></sec><sec id="s7_3"><title>3.3. 拓扑和模块分析</title><p>在网络评价参数中，如果一个节点具有高连接度数和高节点中心度，那么，可能表明该节点在整个网络中具有重要影响。在对共有抗抑靶点PPI图分析中，度较高的四个是NS、ALB、BDNF、IL6。共有抗抑靶点PPI中前10靶点拓扑分析见表2。此外，运用ClusterViz中的MCODE算法进行分析，其中有6类模块的score &gt; 4，这6类不同模块对应的参数如表3所示。</p><p>在越鞠丸特有抗抑靶点PPI中，度较高的是REN、SCNN1A、SCNN1G、SCNN1B与ESR1。在柴胡疏肝散特有抗抑靶点PPI中，度较高的是AKT1、MAPK1、EGF、HRAS与MPO。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Topological analysis of common anti-targets (top 10</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >编号</th><th align="center" valign="middle" >基因</th><th align="center" valign="middle" >连接度</th><th align="center" valign="middle" >介度(介数中心性)</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >INS</td><td align="center" valign="middle" >158</td><td align="center" valign="middle" >0.0851</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >ALB</td><td align="center" valign="middle" >135</td><td align="center" valign="middle" >0.0528</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >BDNF</td><td align="center" valign="middle" >130</td><td align="center" valign="middle" >0.0440</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >IL6</td><td align="center" valign="middle" >118</td><td align="center" valign="middle" >0.0256</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >FOS</td><td align="center" valign="middle" >110</td><td align="center" valign="middle" >0.0236</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >TP53</td><td align="center" valign="middle" >99</td><td align="center" valign="middle" >0.0261</td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >TNF</td><td align="center" valign="middle" >96</td><td align="center" valign="middle" >0.0173</td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >TAC1</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >0.0091</td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >IGF1</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >0.0089</td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >TH</td><td align="center" valign="middle" >87</td><td align="center" valign="middle" >0.0167</td></tr></tbody></table></table-wrap><p>表2. 共有抗抑靶点的拓扑分析(前10)</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Analysis of 6 modules of Yueju Pill and Chaihu Shugan Powde</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >编号</th><th align="center" valign="middle" >模块</th><th align="center" valign="middle" >打分</th><th align="center" valign="middle" >点</th><th align="center" valign="middle" >边</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2270612x15_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >22.407</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >855</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2270612x16_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >19.417</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >586</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2270612x17_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >9.529</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >174</td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2270612x18_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >6.667</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >70</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2270612x19_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >5.917</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >101</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" ><inline-formula><inline-graphic xlink:href="//html.hanspub.org/file/1-2270612x20_hanspub.png" xlink:type="simple"/></inline-formula></td><td align="center" valign="middle" >5.667</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >17</td></tr></tbody></table></table-wrap><p>表3. 越鞠丸和柴胡疏肝散6个模块分析</p></sec><sec id="s7_4"><title>3.4. 共有抗抑靶点通路分析</title><p>每一个模块对应的基因数目为60、49、35、22、25和7。其中第三模块和第六模块暂不对应相应通路，运用DAVID在线平台对每一个模块进行相关通路分析。其中发现不同模块之间也有相同通路，如Calcium信号通路、神经活性配体–受体相互作用和细胞缝隙连接等。而这些通路都已经证明与抑郁症的发病机制相关 [<xref ref-type="bibr" rid="hanspub.39654-ref18">18</xref>]。具体模块通路分析信息如表4所示。该结果表明两种方剂的活性成分可能通过相同的靶点所在的信号通路来发挥抗抑郁的作用。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> The pathway analysis of the common anti-inhibition target</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >编号</th><th align="center" valign="middle" >模块</th><th align="center" valign="middle" >通路</th></tr></thead><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >NR3C1, GHRH, IL13, FOXP3, HTR2A, ADRB3, ADRA1D, ADIPOQ, HTR7, CALCA, ADRA1B, VCAM1, ESR1, SLC18A3, DRD1, ACHE, SLC6A2, ADRA1A, CHRNA4, FOS, SIRT1, IGF1, ADRB1, NOTCH1, IL6, SOD1, CAT, TGFB1, HTR3A, FASLG, ADORA2B, MIF, ADRB2, EPO, FGF2, OPRK1, DRD5, MAOB, OXT, BDNF, ICAM1, PPARG, SOD2, TAC1, HRH2, LEP, HMOX1, MAP2K1, TAAR1, APOE, IL1RN, TLR3, IDO1, PTGS2, MTOR, TNF, CRP, ALB, HTR6, SELP</td><td align="center" valign="middle" >Neuroactiveligand-receptor interaction、Calcium signaling pathway、Pathways in cancer、 Cytokine-cytokine receptor interaction、MAPK signaling pathway、Prion diseases、 Toll-like receptor signaling pathway、Vascular smooth muscle contraction、Adipocytokine signaling pathway、Hypertrophic cardiomyopathy (HCM)、Gap junction、Graft-versus-host disease、Dilated cardiomyopathy、Tryptophan metabolism</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >ADORA1, CHRM2, F2, HTR1A, AGTR2, DRD3, TH, KISS1, DDC, AVPR1A, CNR2, AVP, DBH, PLCB1, ADRA2A, ADRA2C, CCL2, DRD4, IL4, AGTR1, MAOA, HRH1, IL1B, SLC18A2, PF4, HTR1B, IL10, HTR2C, ENSG00000196689, IFNG, PIK3CA, OXTR, PIK3R1, GRM7, COMT, CRH, CHRM4, TACR2, TP53, CHRM1, HTR1D, OPN4, CHRM5, HRH4, DRD2, AGT, SLC6A4, CHRM3, HTR2B</td><td align="center" valign="middle" >Neuroactive ligand-receptor、Calcium signaling pathway、Tyrosine metabolism、Regulation of actin cytoskeleton、Renin-angiotensin system、T cell receptor signaling pathway、Apoptosis、Allograft rejection、Gap junction、Jak-STAT signaling pathway</td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >GRIA4, HTR3B, GRIA3, DNMT1, GNAS, FGFR2, CACNG2, NRXN1, NLGN1, MYOD1, PDGFB, GRIA1, GRIN1, GSR, HOMER1, SHBG, NOS1, SLC1A3, IGF2, SLC17A7, ESR2, CYP19A1, SHH, GABRB2, SLC6A3, EDN1, CAMK2G, GRIN2D, GRIN2C, GRIN2B, SNCA, CACNA1C, RET, GRIA2, BMP4</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >NEFL, CACNA1A, GABRB3, GABRA1, GABRG2, KCNE1L, GRIN2A, KCNA1, KCND3, GABRG3, ABCC9, FMR1, PDE4B, PDE4D, CACNA1H, KCNJ5, SCN2A, DLG4, GABRA3, CACNA1G, HTT, HOMER2</td><td align="center" valign="middle" >Neuroactiveligand-receptor interaction、Calcium signaling pathway</td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >HCRT, GHRL, BCHE, IL5, LTA, NGF, COL1A1, ADORA2A, CNTF, BMP2, MC4R, MAPT, CRHR2, CCL5, NGFR, AR, CNR1, INS, CALB1, ADRA2B, KIT, SOX9, ACE, PPARA, APOA1</td><td align="center" valign="middle" >Calcium signaling pathway、Neuroactiveligand-receptor interaction</td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >KCNH2, KCNQ1, SCN5A, KCND2, SCN1B, SCN8A, ANK3</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表4. 共有抗抑靶点的通路分析</p></sec><sec id="s7_5"><title>3.5. 特有抗抑靶点通路分析</title><p>同样运用DAVID分析得出，越鞠丸潜在抗抑靶点的代谢通路有：醛固酮调节的钠重吸收信号通路(15.00%)、味觉转导信号通路(15.00%) (图6)。柴胡疏肝散潜在抗抑靶点的代谢通路排在前面的有：癌症通路(25.00%)、ErbB信号通路(17.31%)、MAPK信号通路(15.38%)等(图7)。该结果表明越鞠丸和柴胡疏肝散的活性成分可能通过作用于这些特有靶点影响信号通路来达到抗抑郁的效果。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>在临床中发现 [<xref ref-type="bibr" rid="hanspub.39654-ref19">19</xref>] 一些抑郁症患者中的某些因子比正常人来说相对较高，如细胞因子IL-1、TNF-α等，抗炎因子IL-4、IL-8和IL-10都会显著的上升。这就是抑郁症的发病机制推测之一：炎症反应学说。另外还有细胞分子机制学说、脑源性神经营养因子学说等 [<xref ref-type="bibr" rid="hanspub.39654-ref20">20</xref>]。在研究抑郁症的发病原因中，这些学说都有一定的理论依据，从不同的角度上揭示了抗抑郁药物的作用机制。</p><p>图6. 越鞠丸潜在抗抑靶点的KEGG分析</p><p>图7. 柴胡疏肝散潜在抗抑靶点的KEGG分析</p><p>我国一系列针对越鞠丸治疗抑郁症的研究显示，越鞠丸中大部分药物组分包括香附、苍术、川芎、栀子都具有抗抑郁的效果 [<xref ref-type="bibr" rid="hanspub.39654-ref21">21</xref>]。蒋麟发现，在研究越鞠丸之中的组分时，发现并非所有组分都有作用。在对小鼠的行为分析当中，发现只有川芎和栀子有抗抑郁的作用 [<xref ref-type="bibr" rid="hanspub.39654-ref22">22</xref>]，其中栀子起作用可能是脑内脑源性神经生长因子(Brain-derived neuotrophyic factor, BDNF)的表达升高相关 [<xref ref-type="bibr" rid="hanspub.39654-ref23">23</xref>]。脑内脑源性神经生长因子可以通过与特异性受体酪氨酸激酶受体B (Tyrosine Kinase receptor B, TrkB)相互作用来达到维持着神经元存活的作用，其表达水平的提高可改善突触的可塑性，从而产生快速抗抑郁效果 [<xref ref-type="bibr" rid="hanspub.39654-ref24">24</xref>]。尉小慧等提出，醇提越鞠丸将具有更强的抗抑郁效果 [<xref ref-type="bibr" rid="hanspub.39654-ref25">25</xref>]。同时，当前对于治疗抑郁症的相关研究，已证实了柴胡疏肝散也有抗抑郁作用。柴胡疏肝散与部分抗抑郁药物的作用效果相似，无论是单独使用还是与其他抗抑郁药物协同使用，都比空白对照有更好的抗抑郁效果，同时，其降低抑郁症状评分也比某些抗抑郁药物显著 [<xref ref-type="bibr" rid="hanspub.39654-ref26">26</xref>]，这说明柴胡疏肝散的确具有一定程度的抗抑郁作用。研究表明柴胡疏肝散分别与帕罗西汀疗法和艾司西酞普兰可以有效降低抑郁程度 [<xref ref-type="bibr" rid="hanspub.39654-ref27">27</xref>] [<xref ref-type="bibr" rid="hanspub.39654-ref28">28</xref>]。其中与帕罗西汀疗法的联合过程中，通过提高五-羟色胺(5-hydroxytryptamine, 5-HT)的含量来治疗抑郁症。在现代药理学中也证明了在柴胡疏肝散当中的一些成分如芍药内脂苷、柴胡皂苷A等能有效提高5-HT含量，从而达到抗抑郁的目的 [<xref ref-type="bibr" rid="hanspub.39654-ref29">29</xref>] [<xref ref-type="bibr" rid="hanspub.39654-ref30">30</xref>] [<xref ref-type="bibr" rid="hanspub.39654-ref31">31</xref>]。我们可以发现5-HT含量高低与抑郁症紧密相关。如果脑中的5-HT所介导的通路发生异常，意味5-HT的含量降低，那么可能就会导致抑郁症等多疾病的发生 [<xref ref-type="bibr" rid="hanspub.39654-ref32">32</xref>]。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，本研究通过网络药理学和生物信息学数据挖掘技术分析越鞠丸和柴胡疏肝散作用抑郁症的机制。从“同病”的角度来说，两种方剂存在相同抗抑靶点，如INS、ALB、BDNF、IL6、FOS等。这些靶点很可能在其生物通路具有发挥抗抑郁的作用。同时“异治”是由于在每一种方剂当中，又有其特有抗抑靶点所在的生物通路来发挥作用。越鞠丸中的SCNN1G、SCNN1B、SCNN1A蛋白所在的味觉转导信号通路、醛固酮调节的钠重吸收等信号通路发挥抗抑郁的机制。柴胡疏肝散中的AKT1、HRAS、MAPK1蛋白所在的癌症通路、ErbB信号通路等通路发挥抗抑郁的机制。综上，在对越鞠丸和柴胡疏肝散的研究当中，确实能够有效揭示“同病异治”的科学内涵，同时上述所显示的一些靶点所在的生物通路已在相关文献当中证实了其抗抑郁的作用。但由于在筛查靶点的过程中，存在一些成分所对应的靶点过少，导致对研究结果会有一定的限制，所以今后需进一步探讨相关靶点的作用机制来更好地阐释两者抗抑郁的作用。现在发现中药的多成分多靶点的特点与网络药理学多靶点–多途径的研究方法十分切合，所以用网络药理学来研究中药作用机制是一种逻辑性科学性强的选择。同时结合生物信息学、R语言及其数据挖掘方法，筛选疾病表达的差异基因，找到疾病靶点，预测药物作用疾病通路，再构建可视化的计算机网络图，可以更好地分析疾病与药物之间的紧密关系。本研究通过采用网络药理学和生物信息学的信息挖掘技术，对越鞠丸和柴胡疏肝散的化学成分和靶点进行了大量信息整合筛选和预测，通过对靶点和通路的分析初步阐明“同病异治”抑郁症的作用机制，最终以可视化蛋白质互作网络的形式呈现越鞠丸和柴胡疏肝散“同病异治”的作用机制，可用于后续研究的参考。基于网络药理学和生物信息学数据挖掘探索中药作用疾病机制也为今后深入研究中药方剂“同病异治”的作用机制研究提供了一个新的思路与方法。</p></sec><sec id="s10"><title>基金项目</title><p>成都中医药大学科技发展基金(ZRQN2020001)；四川省青年科技创新团队项目(19CXTD0055)。</p></sec><sec id="s11"><title>文章引用</title><p>黄志航,刘文雯,钟 馨,木本荣,王冬梅,国锦琳. 探析越鞠丸和柴胡疏肝散“同病异治”抑郁症的作用机制Analysis of Antidepressant Mechanism of Yueju Pill and Chaihu Shugan Powder in Treating Depression with “the Same Disease with Different Treatments”[J]. 中医学, 2021, 10(01): 1-13. https://doi.org/10.12677/TCM.2021.101001</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39654-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">张磊阳, 蒋健, 贺敏, 李玥. 抗抑郁中药的药理研究进展[J]. 中国实验方剂学杂志, 2017, 23(24): 224-234. 
http://dx.chinadoi.cn/10.13422/j.cnki.syfjx.2017240224</mixed-citation></ref><ref id="hanspub.39654-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">王慧慧, 张百霞, 叶小彤, 何帅兵, 张燕玲, 王耘. 基于“中药作用机理辅助解析系统”的四逆散抗抑郁作用机制研究[J]. 中国中药杂志, 2015, 40(19): 3723-3728. http://dx.chinadoi.cn/10.4268/cjcmm20151906</mixed-citation></ref><ref id="hanspub.39654-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">邱娟. 柴胡疏肝散及拆方对抑郁模型大鼠行为学和脑组织p38MAPK、ERK5表达的影响[D]: [博士学位论文]. 长沙: 中南大学, 2014.</mixed-citation></ref><ref id="hanspub.39654-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">任荔, 陶伟伟, 薛文达, 吴颢昕, 陈刚. 越鞠丸石油醚部位潜在的快速抗抑郁作用与BDNF、TrkB蛋白表达的上调相关[J]. 中国药理学通报, 2015, 31(12): 1754-1759.</mixed-citation></ref><ref id="hanspub.39654-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">张天臣. 运用仲景治未病理论防治糖尿病之探讨及彭万年教授相关学术经验总结[D]: [博士学位论文]. 广州: 广州中医药大学, 2015.</mixed-citation></ref><ref id="hanspub.39654-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">姚春鹏, 译注. 黄帝内经•素问[M]. 北京:中华书局, 2010: 614.</mixed-citation></ref><ref id="hanspub.39654-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">解静, 高杉, 李琳, 徐一兰, 高树明, 于春泉. 网络药理学在中药领域中的研究进展与应用策略[J]. 中草药, 2019, 50(10): 2257-2265. http://dx.chinadoi.cn/10.7501/j.issn.0253-2670.2019.10.001</mixed-citation></ref><ref id="hanspub.39654-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">王俊, 郭丽, 吴建盛, 汤丽华, 胡栋. 大数据背景下的生物信息学研究现状[J]. 南京邮电大学学报(自然科学版), 2017, 37(4): 62-67. http://dx.chinadoi.cn/10.14132/j.cnki.1673-5439.2017.04.011</mixed-citation></ref><ref id="hanspub.39654-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Z.Y., Guo, F.F., Wang, Y., Li, C., Zhang, X., Li, H.L., et al. (2016) BATMAN-TCM: A Bioinformatics Analysis Tool for Molecular Mechanism of Traditional Chinese Medicine. Scientific Reports, 6, Article ID: 21146. 
&lt;br&gt;https://doi.org/10.1038/srep21146</mixed-citation></ref><ref id="hanspub.39654-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Xue, R.C., Fang, Z., Zhang, M.X., Yi, Z.H., Wen, C.P. and Shi, T.L., et al. (2013) TCMID: Traditional Chinese Medicine Integrative Database for Herb Molecular Mechanism Analysis. Nucleic Acids Research, 41, D1089-D1095.  
&lt;br&gt;https://doi.org/10.1093/nar/gks1100</mixed-citation></ref><ref id="hanspub.39654-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">王秋红, 苏阳, 王荔慧, 王长福, 付新, 吴伦, 匡海学. 六神曲中真菌的分离与鉴定[J]. 中国实验方剂学杂志, 2014, 20(7): 122-127. http://dx.chinadoi.cn/10.13422/j.cnki.syfix.2014070122</mixed-citation></ref><ref id="hanspub.39654-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A.C., Liu, Y.F., et al. (2014) Drug Bank 4.0: Shedding New Light on Drug Metabolism. Nucleic Acids Research, 42, D1091-D1097. &lt;br&gt;https://doi.org/10.1093/nar/gkt1068</mixed-citation></ref><ref id="hanspub.39654-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Rebhan, M.,Chalifa-Caspi, V., Prilusky, J. and Lancet, D. (1997) Gene Cards: Integrating Information about Genes, Proteins and Diseases. Trends in Genetics, 13, 163. &lt;br&gt;https://doi.org/10.1016/S0168-9525(97)01103-7</mixed-citation></ref><ref id="hanspub.39654-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Hamosh, A., Scott, A.F., Amberger, J.S. (2002) Online Mendelian Inheritance in Man (OMIM), a Knowledgebase of Human Genes and Genetic Disorders. Nucleic Acids Research, 30, 52-55.  
&lt;br&gt;https://doi.org/10.1093/nar/30.1.52</mixed-citation></ref><ref id="hanspub.39654-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, F., Shi, Z., Qin, C., Tao, L., Liu, X., Xu, F., et al. (2012) Therapeutic Target Database Update 2012: A Resource for Facilitating Target-Oriented Drug Discovery. Nucleic Acids Research, 40, D1128-D1136. 
&lt;br&gt;https://doi.org/10.1093/nar/gkr797</mixed-citation></ref><ref id="hanspub.39654-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J.X., Zhong, J.C., Chen, G., Li, M., Wu, F.X. and Pan, Y. (2015) ClusterViz: A Cytoscape APP for Cluster Analysis of Biological Network. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 12, 815-822. 
&lt;br&gt;https://doi.org/10.1109/TCBB.2014.2361348</mixed-citation></ref><ref id="hanspub.39654-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">章亮, 陈泽慧, 陈韩英, 王晓琴, 张波. 基于网络药理学的白屈菜抗肿瘤分子机制研究[J]. 中草药, 2018, 49(3): 646-657. http://dx.chinadoi.cn/10.7501/j.issn.0253-2670.2018.03.021</mixed-citation></ref><ref id="hanspub.39654-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">高耀, 吴丹, 田俊生, 周玉枝, 高晓霞, 秦雪梅. 逍遥散和开心散“同病异治”抑郁症的网络药理学作用机制研究[J]. 中草药, 2018, 49(15): 3483-3492. http://dx.chinadoi.cn/10.7501/j.issn.0253-2670.2018.15.004</mixed-citation></ref><ref id="hanspub.39654-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Catena-Dell’Osso, M., Bellantuono, C., Consoli, G., et al. (2011) Inflammatory and Neurodegenerative Pathways in Depression: A New Avenue forantidepressant Development. Current Medicinal Chemistry, 18, 245-255. 
&lt;br&gt;https://doi.org/10.2174/092986711794088353</mixed-citation></ref><ref id="hanspub.39654-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Tsao, C.W., Lin, Y.S., Chen, C.C., et al. (2006) Cytokines and Serotonin Transporter in Patients with Major Depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30, 899-905. 
&lt;br&gt;https://doi.org/10.1016/j.pnpbp.2006.01.029</mixed-citation></ref><ref id="hanspub.39654-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">任荔, 吴颢昕, 陈刚. 越鞠丸抗抑郁研究进展[J]. 中国中医基础医学杂志, 2016, 22(10): 1429-1431.</mixed-citation></ref><ref id="hanspub.39654-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">蒋麟. 以越鞠丸为基础的抗抑郁中药复方药理作用及其机理研究[D]: [博士学位论文]. 成都: 成都中医药大学, 2004: 1-59.</mixed-citation></ref><ref id="hanspub.39654-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, H.L., Xue, W.D., Wu, R.J., Gong, T., Tao, W.W., et al. (2015) Rapid Antidepressant Activity of Ethanol Extract of Gardenia jasminoides Ellis Is Associated with Upregulation of BDNF Expression in the Hippocampus. Evidence-Based Complementary and Alternative Medicine, 2015, Article ID: 761238.  
&lt;br&gt;https://doi.org/10.1155/2015/761238</mixed-citation></ref><ref id="hanspub.39654-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">陶伟伟, 肖东, 吴浩然, 沈佳丽, 黄晓燕, 薛文达, 陈刚. 基于药对探讨中药复方越鞠丸抗抑郁作用配伍规律[J]. 中国药理学通报, 2018, 34(9): 1314-1320.</mixed-citation></ref><ref id="hanspub.39654-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">尉小慧, 陈玥, 夏广新, 等. 越鞠丸醇提物与水提物对抑郁模型小鼠的抗抑郁作用比较[J]. 上海中医药杂志, 2006, 40(8):69-70. http://dx.chinadoi.cn/10.3969/j.issn.1007-1334.2006.08.033</mixed-citation></ref><ref id="hanspub.39654-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">金卫东, 邢葆平, 王鹤秋, 陈炯, 童振华, 王乃信. 柴胡疏肝散治疗抑郁症对照研究临床疗效的Meta分析[J]. 中华中医药学刊, 2009, 27(7): 1397-1399.</mixed-citation></ref><ref id="hanspub.39654-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">潘中瑛, 赵婧, 陈静珊. 柴胡疏肝散联合帕罗西汀对抑郁症患者血清5-HT的影响及其安全性分析[J]. 中医药信息, 2018, 35(1): 54-57．</mixed-citation></ref><ref id="hanspub.39654-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">熊盈, 郭蓉娟, 宋大迁, 孙艳, 王鹏宇, 李英. 柴胡疏肝散加减对老年抑郁症患者情绪及生活质量的影响[J]. 世界中西医结合杂志, 2019, 14(9): 1291-1294.</mixed-citation></ref><ref id="hanspub.39654-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">梁卫青, 浦锦宝, 陈宇, 等. 柴胡白芍总皂苷对慢性应激大鼠行为学和海马组织单胺类神经递质的影响[J]. 中华中医药学刊, 2015, 33(8): 1888-1890.</mixed-citation></ref><ref id="hanspub.39654-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Chang, X., Jia, H., Zhou, C., Zhang, H.W., Yu, M., Yang, J.S., et al. (2015) Role of Bai-Shaoof Bai-Shao towards the Antidepressant Effect of Chaihu-Shu-Gan-Sanusing Metabonomics Integrated with Chemical Fingerprinting. Journal of Chromatography B, 1006, 16-29. &lt;br&gt;https://doi.org/10.1016/j.jchromb.2015.10.007</mixed-citation></ref><ref id="hanspub.39654-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">郭超峰, 银胜高, 夏猛, 等. 合欢花总黄酮对抑郁模型大鼠学习记忆能力及血浆单胺类神经递质的影响[J]. 世界科学技术: 中医药现代化, 2013(6): 1318-1322. http://dx.chinadoi.cn/10.11842/wst.2013.06.011</mixed-citation></ref><ref id="hanspub.39654-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Köhler, S., Cierpinsky, K., Kronenberg, G. and Adli, M. (2016) The Serotonergic System in the Neurobiology of Depression: Relevance for Novel Antidepressants. Journal of Psychopharmacology, 30, 13-22. 
&lt;br&gt;https://doi.org/10.1177/0269881115609072</mixed-citation></ref></ref-list></back></article>